ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
3.447
-0.023 (-0.66%)
Jan 31, 2025, 9:54 AM EST - Market open
ImmunityBio Employees
ImmunityBio had 628 employees as of December 31, 2023. The number of employees decreased by 97 or -13.38% compared to the previous year.
Employees
628
Change (1Y)
-97
Growth (1Y)
-13.38%
Revenue / Employee
$11,675
Profits / Employee
-$935,978
Market Cap
2.52B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Dec 31, 2021 | 587 | 322 | 121.51% |
| Dec 31, 2019 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IBRX News
- 2 days ago - ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
- 4 days ago - ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
- 13 days ago - ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval - Seeking Alpha
- 14 days ago - ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
- 15 days ago - ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - Business Wire
- 15 days ago - ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom - Business Wire
- 25 days ago - ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective - Business Wire
- 6 weeks ago - ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha